Armod is a prescription-only wakefulness-promoting agent specifically formulated for adults experiencing excessive sleepiness due to diagnosed shift work sleep disorder (SWSD). Unlike traditional stimulants, Armod enhances alertness by selectively targeting brain receptors involved in the sleep-wake cycle, providing a sustained and smooth transition to wakefulness without the abrupt peaks and crashes associated with older-generation compounds. It is the R-enantiomer of modafinil, offering a more refined pharmacokinetic profile with a longer half-life, making it a first-line therapeutic option for managing work-related circadian disruptions in eligible patient populations. Clinical studies demonstrate its efficacy in improving cognitive performance, vigilance, and overall functional capacity during non-standard waking hours.

Features

• Active ingredient: Armodafinil
• Available in 50mg, 150mg, and 250mg tablet strengths
• Long half-life of approximately 15 hours
• Selective action on dopamine reuptake inhibition
• Minimal impact on other neurotransmitter systems
• Once-daily dosing regimen
• Manufactured under cGMP conditions
• Bioequivalent to reference listed drug
• Shelf-stable formulation
• Child-resistant packaging

Benefits

• Promotes extended periods of wakefulness during night shifts or irregular work schedules
• Enhances cognitive functions including attention, memory, and executive function
• Reduces subjective sleepiness scores as measured by Epworth Sleepiness Scale
• Improves overall occupational performance and safety in shift-work settings
• Minimizes next-day residual sleepiness when taken as directed
• Supports better alignment with non-standard sleep-wake requirements

Common use

Armod is indicated to improve wakefulness in adult patients with excessive sleepiness associated with shift work sleep disorder. It is commonly prescribed for individuals working overnight shifts, rotating shifts, or extended hours that conflict with natural circadian rhythms. The medication is typically taken once daily, approximately one hour before the start of the work shift. It is not approved for use in pediatric populations or for conditions other than those specified in its labeling. Off-label use requires careful risk-benefit assessment by a qualified healthcare provider.

Dosage and direction

The recommended dosage of Armod for shift work sleep disorder is 150mg taken orally once daily, approximately one hour before the start of the work shift. Tablets should be swallowed whole with water and may be taken with or without food, though consistent administration with food may help minimize potential gastrointestinal discomfort. Dosage adjustment may be necessary in patients with severe hepatic impairment, with a recommended reduced dose of 50mg daily. Treatment should be initiated at the lowest effective dose and titrated based on individual response and tolerability. Do not crush, chew, or split tablets.

Precautions

Patients should be monitored for the emergence of new psychiatric symptoms including anxiety, depression, or psychosis. Cardiovascular status should be assessed periodically, particularly in those with pre-existing hypertension or arrhythmias. Use with caution in patients with a history of substance abuse due to potential psychoactive properties. Pregnancy and breastfeeding considerations require thorough discussion with healthcare providers due to limited human data. Patients should avoid alcohol consumption while taking Armod as it may alter drug metabolism and efficacy. Regular evaluation of treatment necessity is recommended, with discontinuation considered during periods of normal sleep-wake cycles.

Contraindications

Armod is contraindicated in patients with known hypersensitivity to armodafinil, modafinil, or any component of the formulation. It should not be used in patients with symptomatic cardiovascular disease, including but not limited to unstable angina, recent myocardial infarction, or uncontrolled arrhythmias. Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C) without appropriate dosage adjustment. Not recommended for patients with left ventricular hypertrophy or mitral valve prolapse syndrome. Avoid use in patients with history of psychosis or mania without adequate psychiatric management.

Possible side effects

Common adverse reactions (≥5%) include headache, nausea, dizziness, insomnia, anxiety, and dry mouth. Less frequently reported effects (1-5%) include palpitations, decreased appetite, diarrhea, nervousness, and hypertension. Serious but rare side effects (<1%) may include Stevens-Johnson syndrome, angioedema, multiorgan hypersensitivity reactions, and psychiatric symptoms including suicidal ideation. Dermatological reactions ranging from mild rash to serious bullous disorders have been reported. Most side effects are dose-dependent and often diminish with continued use or dosage adjustment.

Drug interaction

Armod may reduce the efficacy of hormonal contraceptives (including implants and injectables); alternative non-hormonal contraception is recommended during and for one month after treatment. It may increase metabolism of cyclosporine, warfarin, and certain antidepressants through CYP3A4/5 induction. Concurrent use with MAO inhibitors requires careful monitoring due to theoretical risk of hypertensive crisis. May potentiate effects of sympathomimetic medications. Alcohol may alter armodafinil metabolism and increase risk of adverse reactions. Use with other CNS stimulants may produce additive effects requiring dosage adjustment.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is too close to the next scheduled dose. Do not double the dose to make up for a missed administration. For shift work applications, if remembered during the work shift, it may still be taken unless doing so would interfere with the subsequent sleep period. Consistent timing is important for maintaining therapeutic effect; patients should establish a routine administration schedule aligned with their work hours.

Overdose

Symptoms of overdose may include insomnia, restlessness, confusion, agitation, anxiety, tachycardia, hypertension, and gastrointestinal distress. In severe cases, hallucinations and psychotic symptoms may occur. There is no specific antidote for armodafinil overdose. Management should include symptomatic and supportive care, including cardiovascular monitoring. Gastric lavage may be considered if presentation is early after ingestion. Hospital observation is recommended for significant overdoses due to the long half-life of the medication.

Storage

Store at controlled room temperature 20°-25°C (68°-77°F) with excursions permitted between 15°-30°C (59°-86°F). Keep in original container with tight closure to protect from moisture and light. Do not remove desiccant from packaging. Keep out of reach of children and pets. Do not use beyond the expiration date printed on packaging. Properly dispose of unused medication through take-back programs or according to FDA guidelines.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Armod is available by prescription only and should be used under the supervision of a qualified healthcare provider. Individual response to medication may vary. Patients should consult their healthcare provider for diagnosis and treatment recommendations specific to their medical condition. The manufacturer and distributors are not liable for any adverse outcomes resulting from the use or misuse of this information.

Reviews

Clinical trials demonstrate significant improvement in maintenance of wakefulness test scores compared to placebo. Patient-reported outcomes indicate improved ability to maintain work performance during night shifts. Healthcare providers note improved patient compliance due to once-daily dosing and generally favorable side effect profile. Some patients report decreased efficacy over time, though tolerance development appears less pronounced than with traditional stimulants. Cost considerations may impact long-term adherence for some patient populations.